Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / AMT-130
Other

AMT-130

Tracked across 1 events · 7 articles · First seen Mar 10, 2026 · Last active Mar 31, 2026

Sentiment
-90
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 -90
Regulatory
United States Food and Drug Administration Rebukes uniQure
Impact: AMT-130 is UniQure's lead gene therapy candidate, which the United States — Food and Drug Administration has called a 'failed therapy' due to 'distorted' data and unapproved study design.
Mar 10, 2026 · 7 articles
ERGEN INTELLIGENCE
Track AMT-130 live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.